AMGN · News · 20260825N
Licensing / Collaboration Deals
AMGEN INC · 2026-08-25 · Importance 52 · Surprise 42 · In source text
Amgen terminated its May 2023 research collaboration and license agreement with TScan Therapeutics for Crohn’s disease, effective November 10, 2026. The termination ends Amgen’s exclusive rights to TScan’s T-cell target discovery platform for Crohn’s disease. Amgen is giving up potential milestone payments exceeding US$500 million and future royalties, although third-party reporting characterizes the near-term financial impact as immaterial and frames the decision as a reassessment of long-term R&D priorities.
Key facts
- By terminating the TScan collaboration, Amgen Inc foregoes potential milestones of over US$500 million and future royalties tied to that agreement. source
- Amgen Inc terminated its May 2023 research collaboration and license agreement with TScan Therapeutics concerning Crohn's disease, effective November 10, 2026. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | negative | probable | — | By terminating the TScan collaboration, Amgen Inc foregoes potential milestones of over US$500 million and future royalties tied to that… |